Levosimendan
Levosimendan Brand names, Levosimendan Analogs
Levosimendan Brand Names Mixture
- Alphasel tablets (calcium phosphate [dibasic] + cobalt sulfate + D-alpha tocopheryl acetate + selenium sulfide)
- Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin E + vitamin K1)
Levosimendan Chemical_Formula
C14H12N6O
Levosimendan RX_link
No information avaliable
Levosimendan fda sheet
Levosimendan msds (material safety sheet)
Levosimendan Synthesis Reference
No information avaliable
Levosimendan Molecular Weight
280.285 g/mol
Levosimendan Melting Point
No information avaliable
Levosimendan H2O Solubility
No information avaliable
Levosimendan State
Solid
Levosimendan LogP
2.759
Levosimendan Dosage Forms
Intravenous (loading dose of 12 to 24 micrograms/kg over 10 minutes followed by a continuous infusion of 0.05 to 0.2 micrograms/kg per minute, adjusted according to response)
Levosimendan Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF).
Levosimendan Pharmacology
Levosimendan is a new Ca2+-sensitizing inotropic agent. Ca2+ sensitizers represent a new class of inotropic agents, which overcome the disadvantages associated with currently available inotropic agents in as they are not associated with an increased risk of arrhythmias, cell injury and death due to Ca2+ overload in myocardial cells; they do not increase the activation energy; and they have the potential to reverse contractile dysfunction under pathophysiologic conditions, such as acidosis or myocardial stunning. Levosimendan has not been approved for use in the U.S. or Canada.
Levosimendan Absorption
The bioavailability of oral levosimendan is 85 ± 6% in healthy volunteers and 84 ± 4% in patients.
Levosimendan side effects and Toxicity
No information avaliable
Levosimendan Patient Information
No information avaliable
Levosimendan Organisms Affected
Humans and other mammals
